Central Retinal Vein Occlusion Secondary to Paroxysmal Nocturnal Hemoglobinuria
Ophthalmology Research: An International Journal,
Page 1-7
DOI:
10.9734/or/2022/v16i330234
Abstract
Aims: To describe a Central Retinal Vein Occlusion Secondary to Paroxysmal Nocturnal Hemoglobinuria.
Presentation of Case: A 25 years old, male, student, in regular follow-up in the Hematology sector due to Paroxysmal Nocturnal Hemoglobinuria in regular use of Eculizumab. He reports a month ago that he suddenly noticed, upon waking up in the morning, blurring and decreased visual acuity in her left eye.
Discussion: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder characterized by hemolysis, thrombosis, and bone marrow failure caused by defective expression of glycosylphosphatidylinositol-anchored (GPI-anchored) complement inhibitors. Most commonly, PNH is caused by the loss of PIGA function, which is necessary for GPI biosynthesis.
Conclusions: Patients with hemolytic anemia, unexplained thrombosis, especially in uncommon sites, cytopenias and bone marrow failure syndromes, dysphagia, and unexplained abdominal pain should be screened for PNH. PNH patients can benefit greatly from the treatments available, with a reduction in the risk of serious sequelae and a considerable improvement in their quality of life. So that the patient continues to be followed up in the ophthalmology department, with decreased visual acuity ipsilateral to the lesion, with a relative afferent pupillary defect on that side.
Keywords:
- Thrombosis
- anemia
- paroxysmal nocturnal hemoglobinuria
- retinal central vein occlusion
- complement system
- eculizumab
How to Cite
References
Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: Current treatments and unmet needs. J Manag Care Spec Pharm. 2020;26(12-b Suppl): S14-S20.
Nishimura JI. Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab. Rinsho Ketsueki. 2018; 59(8):1042-1047.
Fattizzo B, Kulasekararaj AG. Second-generation C5 inhibitors for paroxysmal nocturnal hemoglobinuria. BioDrugs. 2020; 34(2):149-158.
Peacock-Young B, Macrae FL, Newton DJ, Hill A, Ariëns RAS. The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source. Haematologica. 2018;103(1):9-17.
Dulau-Florea A, Maric I, Calvo KR, Braylan RC. Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates. Semin Hematol. 2019;56(1): 65-68.
Lee JW, Kulasekararaj AG. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Biol Ther. 2020;20(3):227-237.
Nishimura JI. Antibody therapy for paroxysmal nocturnal hemoglobinuria. Rinsho Ketsueki. 2020;61(8):929-936.
Arcavi M, Ceballo F, Caracciolo MB, Lazarowski A. Paroxysmal nocturnal hemoglobinuria: Test to monitor the action of eculizumab treatment. Int J Lab Hematol. 2020;42(3):335-340.
Kamei RW. Esclerite posterior associada à oclusão da veia central da retina e edema macular cistoide: relato de caso [Posterior scleritis associated with central retinal vein occlusion and cystoid macular edema: case report]. Arq Bras Oftalmol. 2012; 75(5):358-60.
Brunner M, Haueter I, Valmaggia C. Dexamethasonimplantat zur Behandlung des Makulaödems bei retinalen venösen Gefäßverschlüssen und entzündlichen Augenerkrankungen [Dexamethason implant in the treatment of macular edema in retinal vein occlusion and intraocular inflammatory disease]. Klin Monbl Augenheilkd. 2013;230(4):396-400.
Iijima H. Mechanisms of vision loss in eyes with macular edema associated with retinal vein occlusion. Jpn J Ophthalmol. 2018; 62(3):265-273.
Noma H, Funatsu H, Mimura T, Shimada K. Visual function and serous retinal detachment in patients with branch retinal vein occlusion and macular edema: A case series. BMC Ophthalmol. 2011; 11:29.
Zou X, Dai RP, Dong FT. Correlation between photoreceptor layer and visual acuity in eyes with persistent cystoid macular edema secondary to branch retinal vein occlusion. Zhonghua Yan Ke Za Zhi. 2010;46(11): 1006-10.
Lee SE, Lee JW. Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Expert Opin Drug Saf. 2021;20(2):171-179.
Kirito K. Expansion of paroxysmal nocturnal hemoglobinuria clones in MPLW515L mutation harboring primary myelofibrosis. Ann Hematol. 2020;99(11): 2707-2709.
Chauhan AJ, Wiffen LJ, Brown TP. COVID-19: A collision of complement, coagulation and inflammatory pathways. J Thromb Haemost. 2020;18(9):2110-2117.
Rosa J, Arruda A, Rodrigues AL, Soares MR. Paroxysmal Nocturnal Hemoglobinuria: Case Report of a Rare Cause of Thrombosis in the Pediatric Age. J Pediatr Hematol Oncol. 2021;43(2):e240-e242.
Kurashige Y, Tsujikawa A, Murakami T, Miyamoto K, Ogino K, Muraoka Y, et al. Changes in visual acuity and foveal photoreceptor integrity in eyes with chronic cystoid macular edema associated with retinal vein occlusion. Retina. 2012;32(4): 792-8.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Chan CK; SCORE2 Investigator Group. Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial. JAMA Ophthalmol. 2019;137(12):1389-1398.
Etheridge T, Dobson ETA, Wiedenmann M, Oden N, VanVeldhuisen P, Scott IU, et al. Ellipsoid zone defects in retinal vein occlusion correlates with visual acuity prognosis: SCORE2 Report 14. Transl Vis Sci Technol. 2021;10(3):31.
Braithwaite T, Nanji AA, Lindsley K, Greenberg PB. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2014;5(5): CD007325.
Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev. 2013;(1): CD009510.
Tomazos I, Sierra JR, Johnston KM, Cheung A, Brodsky RA, Weitz IC. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab. Hematology. 2020; 25(1):327-334.
Fattizzo B, Serpenti F, Giannotta JA, Barcellini W. Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties. J Clin Med. 2021; 10(5):948.
-
Abstract View: 78 times
PDF Download: 25 times
